20043812|t|The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
20043812|a|BACKGROUND: Amyloid beta(40) (Abeta(40)) is the most abundant Abeta peptide in the brain. The cerebrospinal fluid (CSF) level of Abeta(40) might therefore be considered to most closely reflect the total Abeta load in the brain. Both in Alzheimer's disease (AD) and in normal aging the Abeta load in the brain has a large inter-individual variability. Relating Abeta(42) to Abeta(40) levels might consequently provide a more valid measure for reflecting the change in Abeta metabolism in dementia patients than the CSF Abeta(42) concentrations alone. This measure may also improve differential diagnosis between AD and other dementia syndromes, such as vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). OBJECTIVE: To investigate the diagnostic value of the CSF Abeta(42)/Abeta(40) ratio in differentiating AD from controls, VaD, DLB and FTD. METHODS: We analysed the CSF Abeta(42)/Abeta(40) ratio, phosphorylated tau(181) and total tau in 69 patients with AD, 26 patients with VaD, 16 patients with DLB, 27 patients with FTD, and 47 controls. RESULTS: Mean Abeta(40) levels were 2850 pg/ml in VaD and 2830 pg/ml in DLB patients, both significantly lower than in AD patients (3698 pg/ml; p<0.01). Abeta(40) levels in AD patients were not significantly different from those in controls (4035 pg/ml; p=0.384). The Abeta(42)/Abeta(40) ratio was significantly lower in AD patients than in all other groups (p <0.001, ANCOVA). Differentiating AD from VaD, DLB and non-AD dementia improved when the Abeta(42)/Abeta(40) ratio was used instead of Abeta(42) concentrations alone (p<0.01) The Abeta(42)/Abeta(40) ratio performed equally well as the combination of Abeta(42), phosphorylated tau(181) and total tau in differentiating AD from FTD and non-AD dementia. The diagnostic performance of the latter combination was not improved when the Abeta(42)/Abeta(40) ratio was used instead of Abeta(42) alone. CONCLUSION: The CSF Abeta42/Abeta40 ratio improves differentiation of AD patients from VaD, DLB and non-AD dementia patients, when compared to Abeta42 alone, and is a more easily interpretable alternative to the combination of Abeta42, p-tau and t-tau when differentiating AD from either FTD or non-AD dementia.
20043812	74	93	Alzheimer's disease	Disease	MESH:D000544
20043812	99	123	non-Alzheimer's dementia	Disease	MESH:D000544
20043812	187	192	Abeta	Gene	351
20043812	328	333	Abeta	Gene	351
20043812	361	380	Alzheimer's disease	Disease	MESH:D000544
20043812	382	384	AD	Disease	MESH:D000544
20043812	410	415	Abeta	Gene	351
20043812	485	494	Abeta(42)	Gene	351
20043812	592	597	Abeta	Gene	351
20043812	612	620	dementia	Disease	MESH:D003704
20043812	621	629	patients	Species	9606
20043812	643	652	Abeta(42)	Gene	351
20043812	736	738	AD	Disease	MESH:D000544
20043812	749	767	dementia syndromes	Disease	MESH:D003704
20043812	777	794	vascular dementia	Disease	MESH:D015140
20043812	796	799	VaD	Disease	MESH:D015140
20043812	802	827	dementia with Lewy bodies	Disease	MESH:D020961
20043812	829	832	DLB	Disease	MESH:D020961
20043812	839	862	frontotemporal dementia	Disease	MESH:D057180
20043812	864	867	FTD	Disease	MESH:D057180
20043812	928	937	Abeta(42)	Gene	351
20043812	973	975	AD	Disease	MESH:D000544
20043812	991	994	VaD	Disease	MESH:D015140
20043812	996	999	DLB	Disease	MESH:D020961
20043812	1004	1007	FTD	Disease	MESH:D057180
20043812	1038	1047	Abeta(42)	Gene	351
20043812	1080	1083	tau	Gene	4137
20043812	1099	1102	tau	Gene	4137
20043812	1109	1117	patients	Species	9606
20043812	1123	1125	AD	Disease	MESH:D000544
20043812	1130	1138	patients	Species	9606
20043812	1144	1147	VaD	Disease	MESH:D015140
20043812	1152	1160	patients	Species	9606
20043812	1166	1169	DLB	Disease	MESH:D020961
20043812	1174	1182	patients	Species	9606
20043812	1188	1191	FTD	Disease	MESH:D057180
20043812	1260	1263	VaD	Disease	MESH:D015140
20043812	1282	1285	DLB	Disease	MESH:D020961
20043812	1286	1294	patients	Species	9606
20043812	1329	1331	AD	Disease	MESH:D000544
20043812	1332	1340	patients	Species	9606
20043812	1383	1385	AD	Disease	MESH:D000544
20043812	1386	1394	patients	Species	9606
20043812	1478	1487	Abeta(42)	Gene	351
20043812	1531	1533	AD	Disease	MESH:D000544
20043812	1534	1542	patients	Species	9606
20043812	1604	1606	AD	Disease	MESH:D000544
20043812	1612	1615	VaD	Disease	MESH:D015140
20043812	1617	1620	DLB	Disease	MESH:D020961
20043812	1629	1640	AD dementia	Disease	MESH:D000544
20043812	1659	1668	Abeta(42)	Gene	351
20043812	1705	1714	Abeta(42)	Gene	351
20043812	1749	1758	Abeta(42)	Gene	351
20043812	1820	1829	Abeta(42)	Gene	351
20043812	1846	1849	tau	Gene	4137
20043812	1865	1868	tau	Gene	4137
20043812	1888	1890	AD	Disease	MESH:D000544
20043812	1896	1899	FTD	Disease	MESH:D057180
20043812	1908	1919	AD dementia	Disease	MESH:D000544
20043812	2000	2009	Abeta(42)	Gene	351
20043812	2046	2055	Abeta(42)	Gene	351
20043812	2083	2090	Abeta42	Gene	351
20043812	2133	2135	AD	Disease	MESH:D000544
20043812	2136	2144	patients	Species	9606
20043812	2150	2153	VaD	Disease	MESH:D015140
20043812	2155	2158	DLB	Disease	MESH:D020961
20043812	2167	2178	AD dementia	Disease	MESH:D000544
20043812	2179	2187	patients	Species	9606
20043812	2206	2213	Abeta42	Gene	351
20043812	2290	2297	Abeta42	Gene	351
20043812	2336	2338	AD	Disease	MESH:D000544
20043812	2351	2354	FTD	Disease	MESH:D057180
20043812	2362	2373	AD dementia	Disease	MESH:D000544
20043812	Association	MESH:D003704	351
20043812	Association	MESH:D000544	351

